


# Diabetic Retinopathy as a Residual Microvascular Condition

Yohei Tomita, MD. Ph.D.

Residual Risk Reduction Initiative (R3i) Foundation,  
Basel, Switzerland





# Preface

This booklet, a project of the Residual Risk Reduction Initiative (R3i), is designed to significantly increase awareness and understanding of diabetic retinopathy (DR) as a persistent and often overlooked residual microvascular condition. DR remains a leading cause of preventable vision loss, and our initiative is dedicated to equipping healthcare professionals with the knowledge necessary to not only identify and effectively manage this complex disease, but to ultimately reduce its devastating impact on patients' lives. We firmly believe that a proactive, multi-faceted approach to risk reduction is absolutely essential in preserving vision and dramatically improving outcomes for individuals living with diabetes.

The content presented within this resource provides a comprehensive overview of key aspects of DR, systematically covering everything from its underlying pathophysiology and classification based on severity, to the critical risk factors that contribute to its progression. The booklet also offers a detailed exploration of current best practices in diagnostic methodologies and highlights both established and innovative treatment strategies for managing DR at various stages. It aims to offer a current perspective on the disease, showcasing both firmly rooted established knowledge, alongside emerging trends and promising breakthroughs in the field. While substantial progress has been made in the realm of DR treatment, it's imperative to acknowledge that the condition remains a complex and challenging one, requiring ongoing vigilance and a commitment to continuous learning and improvement in patient care.





# Contents

<b>INTRODUCTION</b> . . . . .	<b>7</b>
<b>SECTION 1:</b> Physiopathology and Mechanisms of Diabetic Retinopathy .	<b>13</b>
<b>SECTION 2:</b> Classification of Diabetic Retinopathy . . . . .	<b>19</b>
<b>SECTION 3:</b> Risk Factors of Diabetic Retinopathy Progression . . . . .	<b>23</b>
<b>SECTION 4:</b> Diagnosis of Diabetic Retinopathy . . . . .	<b>33</b>
<b>SECTION 5:</b> Treatment and Management of Diabetic Retinopathy . . . .	<b>43</b>
<b>SECTION 6:</b> Prevention of Diabetic Retinopathy and Future Treatments .	<b>59</b>
<b>SECTION 7:</b> Others . . . . .	<b>79</b>
<b>ABBREVIATIONS</b> . . . . .	<b>85</b>



# Introduction

## The importance of awareness of diabetic retinopathy (DR)

- Diabetic retinopathy (DR) is a leading cause of vision loss worldwide, highlighting the necessity of public and professional awareness for early detection and intervention.
- Significant regional variations in DR-induced blindness (ranging from 2% to 5.5%), along with its higher prevalence in older populations, underscore the need for targeted screening programs and health education initiatives<sup>1</sup>.
- The substantial socioeconomic burden imposed by DR, coupled with its rising prevalence in aging populations, highlights the urgent need for improved awareness to support early treatment strategies and optimize current management protocols (e.g., laser therapy, anti-VEGF treatment, steroids, and vitrectomy)<sup>2</sup>.

1. Leasher JL, et al. *Diabetes Care* 2016. 2. Tomita Y, et al. *J Clin Med* 2021.

**R3i**  
Residual Risk Reduction Initiative

## The importance of awareness of diabetic retinopathy (DR)

The importance of awareness regarding diabetic retinopathy (DR) as a major cause of vision loss worldwide. It highlights the need for public and professional awareness for early detection and intervention.

The prevalence of DR-related blindness varies regionally (2%–5.5%) and is higher in older populations, underscoring the necessity of targeted screening programs and health education.

Additionally, the socioeconomic burden of DR and its increasing prevalence in aging populations stress the urgency for improved awareness to support early treatment strategies and optimize management, including laser therapy, anti-VEGF treatment, steroids, and vitrectomy.

### References:

1. Leasher JL, et al. *Diabetes Care* 2016.
2. Tomita Y, et al. *J Clin Med* 2021.

## A brief definition and overview

- The overall prevalence of any diabetic retinopathy was estimated at 34.6%, with proliferative diabetic retinopathy observed in 6.96%, diabetic macular edema in 6.81%, and vision-threatening diabetic retinopathy in 10.2%<sup>1</sup>.
- According to the Vision Loss Expert Group (VLEG), diabetic retinopathy (DR) accounts for 1.25% of moderate-to-severe visual impairment and 1.07% of blindness worldwide<sup>2</sup>.
- A meta-analysis has shown that the proportion of blindness attributable to DR varies by region, ranging from 2% in Oceania and East/Southeast Asia to 5.5% in Southern Latin America<sup>3</sup>.
- The prevalence of DR differs by diabetes type, affecting approximately 42.1% of type 1 diabetes mellitus (DM) cases and 25.5% of type 2 DM cases<sup>4</sup>.

1. Yau *et al. Diabetes Care* 2012. 2. Bourne RRA, *et al. Lancet Glob Health* 2017.  
3. Leasher JL, *et al. Diabetes Care* 2016. 4. Ziets B, *et al. Dtsch Med, Wochenschr* 2000.

**R<sup>3</sup>i**  
Resilient Risk Reduction Initiative

## A brief definition and overview

Among 35 studies conducted between 1980 and 2008, data were obtained from 22,896 individuals with diabetes. The overall prevalence of any diabetic retinopathy was estimated at 34.6% (95% CI, 34.5–34.8), with proliferative diabetic retinopathy observed in 6.96% (95% CI, 6.87–7.04), diabetic macular edema in 6.81% (95% CI, 6.74–6.89), and vision-threatening diabetic retinopathy in 10.2% (95% CI, 10.1–10.3).


According to the Vision Loss Expert Group (VLEG), DR contributes to 1.25% of moderate-to-severe visual impairment and 1.07% of global blindness.

A meta-analysis indicates regional variability in the proportion of blindness due to DR, ranging from 2% in Oceania and East/Southeast Asia to 5.5% in Southern Latin America. Additionally, the prevalence of DR differs by diabetes type, affecting approximately 42.1% of type 1 diabetes mellitus (DM) cases and 25.5% of type 2 DM cases.

### References:

1. Yau *et al. Diabetes Care* 2012.
2. Bourne RRA, *et al. Lancet Glob Health* 2017.
3. Leasher JL, *et al. Diabetes Care* 2016.
4. Ziets B, *et al. Dtsch Med, Wochenschr* 2000.

## Epidemiology of diabetic retinopathy in Japan



1. Hashimoto S, et al. *Graefes Arch Clin Exp Ophthalmol* 2023. 2. Kawasaki R, et al. *Diabetologia* 2011.  
3. Morizane Y, et al. *Jpn J Ophthalmol* 2019.

**R3i**  
Residual Risk Reduction Initiative

## Epidemiology of diabetic retinopathy in Japan


In Japan, the prevalence of diabetic retinopathy (DR) decreased from 27.4% in 1998 to 6.4% in 2017. The annual incidence rate is 3.83%, with a progression rate of 2.11% per year from mild/moderate NPDR to severe NPDR or PDR.

DR is the third leading cause of blindness, accounting for 12.8% of cases.

### References:

1. Hashimoto S, et al. *Graefes Arch Clin Exp Ophthalmol* 2023.
2. Kawasaki R, et al. *Diabetologia* 2011.
3. Morizane Y, et al. *Jpn J Ophthalmol* 2019.

## The number of Proliferative Diabetic Retinopathy (PDR) patients is decreasing worldwide



About T, et al. *International Journal of Retina and Vitreous* 2024.

**R<sup>3</sup>i**  
Realized Risk Reduction Initiative

## The number of Proliferative Diabetic Retinopathy (PDR) patients is decreasing worldwide

This slide illustrates the global decline in proliferative diabetic retinopathy (PDR) incidence, attributed to advancements in diabetes management and ophthalmologic treatments. Improved glycemic and blood pressure control have reduced microvascular complications.

Additionally, systematic screening, laser therapy, and anti-VEGF treatments have enhanced early detection and management. However, severe cases, especially in younger patients, often lead to blindness, making early detection and early intervention essential.

### References:

1. About T, et al. *International Journal of Retina and Vitreous* 2024.





# **Physiopathology and Mechanisms of Diabetic Retinopathy**


**SECTION**

**1**

**R<sup>3</sup>i**

Residual Risk Reduction Initiative

## Clinical appearance of Diabetic Retinopathy



## Clinical appearance of Diabetic Retinopathy

### Pathophysiology of Diabetic Retinopathy (DR)

Diabetic retinopathy (DR) is classified into mild, moderate, and severe non-proliferative diabetic retinopathy (NPDR), as well as the advanced stage, proliferative diabetic retinopathy (PDR).


During the mild to moderate stages, hyperglycemia induces endothelial cell damage and pericyte loss, leading to microaneurysm formation and increased vascular permeability. As the disease progresses, vascular occlusion occurs, resulting in widespread retinal ischemia, marking the transition to the severe stage. In response to ischemia, excessive vascular endothelial growth factor (VEGF) production triggers neovascularization, leading to the PDR stage. These newly formed blood vessels are fragile and prone to hemorrhage, which can cause retinal detachment and, if left untreated, lead to blindness.

Additionally, regardless of the disease stage, plasma components can leak into the retina, leading to macular edema. This condition affects the macula, the most crucial part of the retina, and can result in significant visual impairment.

### References:

1. Tomita et al. *Jpn J Ophthalmol* 2010.
2. Arcadu, et al. *NPJ Digit Med* 2019.

## Schematic representation of diabetic retinopathy progression



## Schematic representation of diabetic retinopathy progression


Hyperglycemia induces oxidative stress, epigenetic modifications, and inflammation in endothelial cells (ECs), leading to neuroglial degeneration. Pericyte loss sensitizes ECs to environmental cues, while macrophages secrete VEGFA and PlGF, exacerbating vascular instability.

Angiopoietin-2 (Ang2) and FOXO1 form a destabilizing loop, contributing to blood-retina barrier breakdown. Hypoxia from vessel occlusion triggers extra-retinal neovascularization and fibrovascular membrane formation. VEGFR2-mediated MAPK and PI3K/Akt signaling drives angiogenesis and vascular leakage.

### References:

1. Kusuhara S, et al. *Diabetes Metab J* 2018.

## VEGF: a key molecular target in neovascularization




## VEGF: a key molecular target in neovascularization

Vascular network formation requires vessel sprouting, maturation, and remodeling. Tip cells (Tie2 low, VEGFR2/3 high) lead stalk cells (Tie2 high) in response to a VEGF gradient. VEGF signaling induces Dll4 expression, which activates Notch1 in stalk cells, suppressing VEGFR2/3 and tip cell fate.

Tip cells anastomose, while stalk cells proliferate to elongate the sprout and form a lumen. Vessel stabilization occurs through mural cell recruitment (SMCs, pericytes) regulated by PDGF/PDGFR $\beta$ , Ang-1/Tie2, and TGF- $\beta$  signaling.

### References:

1. Joussen A M, *et al.* Eye 2021.



### Pathophysiological mechanisms leading to DME


Retinal edema is a consequence of an imbalance between fluid entry, fluid exit and retinal hydraulic conductivity.

In most retinal diseases, macular edema is multifactorial and results from multiple, intricate mechanisms, but in certain specific conditions, one single of these mechanisms predominates, allowing a better analysis of each component.

#### References:

1. Daruich A, et al. *Prog Retin Eye Res* 2018.

## Summary of DR pathophysiology



## Summary of DR pathophysiology

Hyperglycemia activates metabolic pathways (AGEs, PKC, polyol, hexosamine), leading to microvascular damage, inflammation, and glutamate excitotoxicity. This results in pericyte/endothelial cell loss, basement membrane thinning, increased inflammatory cytokines (IL-6, IL-1, CCL-2, TNF- $\alpha$ ), vascular permeability, and VEGF-driven neovascularization.

### DR progresses through stages:

- **NPDR (Non-Proliferative DR):** Microaneurysms (mild), hemorrhages (moderate), venous beading and vascular abnormalities (severe).
- **PDR (Proliferative DR):** Neovascularization, vitreous hemorrhage, and retinal detachment.
- **DME (Diabetic Macular Edema):** Retinal thickening causing vision loss at any stage.

Lipid metabolism abnormalities may further worsen retinal damage. DR development involves complex, interrelated mechanisms of metabolic dysfunction, inflammation, and angiogenesis.

### References:

1. Tomita, *et al.* J Clin Med 2021.

# Classification of Diabetic Retinopathy

SECTION

2

**R<sup>3</sup>i**

Residual Risk Reduction Initiative

## History of classification of DR

- **1969** Airlie House classification  
Goldberg MF, *et al. Ophthalmology* 1987
- **1981** Modified Airlie House classification  
DR study, *Invest Ophthalmol Vis Sci* 1981
- **1991** ETDRS; Early Treatment Diabetic Retinopathy Study  
ETDRS research group, *Ophthalmology* 1991
- **2002** International Clinical Diabetic Retinopathy and Diabetic Macular Edema Disease Severity Scale (ICDR classification)  
Wilkinson CP, *et al. Ophthalmology* 2003

**R<sup>3</sup>i**

Residual Risk Reduction Initiative


## History of classification of DR

The classification of DR has evolved from the Airlie House system to the widely used ETDRS and ICDR classifications, improving the assessment of disease severity and management strategies.

The ICDR classification is currently used worldwide.



## International Clinical Diabetic Retinopathy and Diabetic Macular Edema Disease Severity Scale




## International Clinical Diabetic Retinopathy and Diabetic Macular Edema Disease Severity Scale

The **International Clinical Diabetic Retinopathy (ICDR) Disease Severity Scale** categorizes DR into **non-proliferative (mild, moderate, severe)** and **proliferative (PDR)** stages, based on fundoscopic findings. Representative retinal images illustrate the progression from **DR absence to advanced PDR**, with increasing severity of hemorrhages, venous beading, and neovascularization.

Diabetic **macular edema (DME)**, characterized by retinal thickening, can occur at any stage of DR and significantly impacts vision. The **ICDR classification (Wilkinson *et al.* 2003)** remains the global standard for assessing DR severity and guiding treatment decisions.

### References:

1. Tomita *et al.* *Jpn J Ophthalmol* 2010.
2. Arcadu, *et al.* *NPJ Digit Med* 2019.
3. Wilkinson CP, *et al.* *Ophthalmology* 2003.



### New Classification of DR

A new classification of DR has been proposed, emphasizing **both vascular damage and neural dysfunction**. DR should not only be evaluated based on vascular pathology but also on **diabetic retinal neurodegeneration (DRN)**. This broader perspective introduces the term **diabetic retinal disease (DRD)**, which encompasses both **diabetic retinopathy (DR)** and **DRN**.

The 3D model illustrates the relationship between **systemic health**, **vascular function**, and **neural function**, showing how worsening systemic conditions contribute to disease progression and visual impairment.

#### References:

1. Sun JK, *et al. Ophthalmology* 2020.

# Risk Factors for Diabetic Retinopathy Progression

SECTION

3

**R<sup>3</sup>i**

Residual Risk Reduction Initiative

## There are various risk factors for DR

- Hyperglycemia
- Severe hypoglycemia
- Hypertension
- Hyperlipidemia
- Renal dysfunction
- Anemia
- Pregnancy
- Smoking

**R3i**

Retinal Risk Reduction Initiative

## There are various risk factors for DR

These are the major risk factors for the progression of diabetic retinopathy (DR). Poor glycemic control (hyperglycemia) remains the most critical factor, while episodes of severe hypoglycemia may also disrupt stable metabolic regulation, leading to further retinal damage.

Additional systemic contributors—such as hypertension, hyperlipidemia, and renal dysfunction—worsen vascular compromise in the retina. Anemia can exacerbate retinal ischemia by reducing oxygen delivery, and pregnancy is known to accelerate DR progression, particularly when glycemic control is suboptimal.

Finally, smoking increases oxidative and vascular stress, further driving DR pathology. Effective management of these risk factors is crucial to slow DR progression and preserve visual function.

## Risk factors for DR (meta-analysis of 35 studies)

### Prevalence of any DR increased with:

- Longer diabetes duration (21.1% for <10 years vs. 76.3% for ≥20 years)
- Higher HbA1c levels (18.0% for ≤7.0% vs. 51.2% for >9.0%)
- Higher blood pressure (30.8% for ≤140/90 mmHg vs. 39.6% for >140/90 mmHg)
- Type 1 diabetes (77.3%) compared to type 2 diabetes (25.2%)

A trend of higher vision-threatening DR (VTDR) prevalence was noted in individuals with cholesterol levels ≥4.0 mmol/L.

A decline in DR prevalence was observed in the post-2000 era.

22,896 individuals with diabetes  
 34.6% (95% CI 34.5–34.8) for any DR  
 6.96% (6.87–7.04) for proliferative DR  
 6.81% (6.74–6.89) for diabetic macular edema  
 10.2% (10.1–10.3) for VTDR

Yau J, et al. *Diabetes Care* 2012.

**R<sup>3</sup>i**  
 Realized Risk Reduction Initiative

## Risk factors for DR (meta-analysis of 35 studies)

The age-standardized prevalence of diabetic retinopathy (DR) across various risk factors and subgroups. The prevalence of DR varies by ethnicity, with the highest rates observed among African Americans and the lowest among Asians. The prevalence also increases with diabetes duration, rising from 21.1% in those with less than 10 years of diabetes to 76.3% in those with 20 or more years.

Similarly, higher HbA1c levels are associated with increased prevalence, with 18.0% in individuals with HbA1c ≤7.0% compared to 51.2% in those with levels >9.0%. Blood pressure is another significant factor, as individuals with hypertension (>140/90 mmHg) exhibit a higher prevalence (39.6%) compared to those with normal blood pressure (30.8%). Furthermore, the prevalence is markedly higher in individuals with type 1 diabetes (77.3%) compared to type 2 diabetes (25.2%).


A similar pattern is observed for more advanced stages of DR, including proliferative diabetic retinopathy (PDR), diabetic macular edema (DME), and vision-threatening DR (VTDR). Notably, VTDR prevalence is higher among individuals with cholesterol levels ≥4.0 mmol/L. Additionally, an analysis by year and period of fundus photography suggests a decline in DR prevalence in the post-2000 era, likely reflecting improvements in diabetes management and screening strategies.

### References:

1. Yau J, et al. *Diabetes Care* 2012.

## Clinical stages of diabetic retinopathy

- Severe hypoglycemia increases the risk of developing DR, as demonstrated in the JDCS study (Tanaka S, *et al. Diabetes & Metabolism* 2017).
- Rapid improvement in glycemic control can lead to an initial worsening of DR, a phenomenon known as 'early worsening'.



EWDR: Early worsening DR  
Simo, *et al. Diabetes Care* 2023.

**R3i**  
Residual Risk Reduction Initiative

## Clinical stages of diabetic retinopathy

Although tight glycemic control remains essential for preventing the progression of DR, lowering blood glucose too rapidly can be problematic. Severe hypoglycemia has been reported to increase the risk of DR onset by 4.35-fold, and abrupt glycemic reductions may trigger “early worsening,” an initial exacerbation of DR before subsequent stabilization.

While maintaining a low HbA1c over the long term is generally beneficial, recent evidence suggests that if patients are classified as having moderate NPDR or less, rapid glycemic control does not significantly raise the risk of early worsening. These findings highlight the importance of detailed fundus examinations and accurate DR grading, which guide appropriate timing and intensity of glycemic management in collaboration with internal medicine specialists.

### References:

1. Simo, *et al. Diabetes Care* 2023.

## Renal dysfunction and DR

- The risk of DR progression increases with elevated microalbuminuria and reduced glomerular filtration rate (GFR).  
*Chen, et al. PLoS One 2012; Man, et al. Invest Ophthalmol Vis Sci 2015.*
- The presence of nephropathy increases the risk of progression to Proliferative DR (PDR) by approximately 30%.  
*Nwanyanwu, et al. Diabetes Care 2013.*
- In patients with type 2 diabetes with proteinuria, the presence of DR is associated with an accelerated decline in GFR.  
*Trevisan, et al. Diabetes Care 2002.*

**R<sup>3</sup>i**  
Residual Risk Reduction Initiative

## Renal dysfunction and DR

Microalbuminuria and reduced glomerular filtration rate (GFR) significantly increase the risk of DR. The presence of nephropathy elevates the likelihood of advancing to proliferative DR (PDR) by approximately 30%.

Furthermore, in patients with type 2 diabetes who exhibit proteinuria, concurrent DR accelerates the decline in GFR. These findings underscore the importance of monitoring and managing renal function to mitigate the progression of DR.

## Renal function deterioration contributes to progression of DR

Characteristics	From no DR to NPDR		From NPDR to PDR	
	Univariate Odds ratio (95% CI)	Multivariate Odds ratio (95% CI)	Univariate Odds ratio (95% CI)	Multivariate Odds ratio (95% CI)
Age (per year)	0.999 (0.981-1.018)		0.953 (0.926-0.980)*	0.966 (0.937-0.995)*
Duration of diabetes (per year)	1.067 (1.037-1.098)*	1.062 (1.025-1.100)*	0.995 (0.995-1.037)	
FPG (per mg/dl)	1.006 (1.003-1.008)*	1.003 (1.000-1.007)	1.003 (0.999-1.007)	
HbA1c (per %)	1.401 (1.261-1.557)*	1.353 (1.191-1.537)*	1.210 (1.028-1.426)*	1.111 (0.933-1.323)
Albuminuria (vs. no)	3.843 (1.889-7.819)*	2.791 (1.244-6.263)*	1.993 (0.908-4.376)	
eGFR (per ml/min/1.73m <sup>2</sup> )	0.993 (0.982-1.003)		0.998 (0.983-1.013)	
Decrease eGFR >20% (vs. no)	1.953 (1.005-3.796)*	0.879 (0.373-2.075)	3.423 (1.696-6.908)*	2.553 (1.219-5.348)*

- A retrospective observational study conducted in South Korea over 8 years
- 1,527 patients with type 2 diabetes

\*p<0.05. Abbreviation: DR: diabetic retinopathy; NPDR: nonproliferative diabetic retinopathy; PDR: proliferative diabetic reinopathy; FPG: fasting plasma glucose; hemoglobin A1c: HbA1c; eGFR: estimated glomerular filtrate rate  
Cho A, et al. *J Diabetes Res* 2020.



## Renal function deterioration contributes to progression of DR


A retrospective observational study in South Korea followed 1,527 patients with type 2 diabetes over eight years. The findings indicate that renal function deterioration—reflected by albuminuria and a more than 20% decline in eGFR—significantly increases the risk of progressing from DR.

These results underscore the critical role of kidney function in DR pathogenesis and highlight the need for careful renal monitoring and management in diabetic patients to mitigate the progression of retinopathy.

### References:

1. Cho A, et al. *J Diabetes Res* 2020.





### Anemia is a risk factor for the progression of DR in patients with type 2 diabetes

Data from Wang J. et al. indicate that lower hemoglobin levels (i.e., anemia) are associated with a higher prevalence of both non-proliferative and proliferative DR in patients with type 2 diabetes.

These findings underscore the importance of monitoring and managing hemoglobin levels to mitigate DR progression.

#### References:

1. Wang J, et al. *Invest Ophthalmol Vis Sci* 2020.

## Pregnancy is a risk factor for DR progression

- Pregnant patients have a 1.60- to 2.48- fold higher risk of DR progression compared to nonpregnant patients.  
The Diabetes Control and Complications Trial Research Group *Diabetes Care* 2000.
- Improvements in perinatal glycemic management have reduced the frequency of DR progression compared to the past.  
Toda J, *et al. Jpn J Ophthalmol* 2016.
- Despite advances in diabetes management, DR progresses more rapidly in pregnant women with diabetes than in nonpregnant individuals with diabetes, emphasizing the need for improved management during pregnancy.  
Widyaputri F, *et al. JAMA Ophthalmol* 2022.

Tomita, *et al. J Clin Med* 2021.

**R3i**  
Residual Risk Reduction Initiative

## Pregnancy is a risk factor for DR progression

Pregnancy significantly increases the risk of diabetic retinopathy (DR) progression, with pregnant individuals experiencing a 1.60- to 2.48-fold higher likelihood of advancing DR compared to nonpregnant patients.

Advances in perinatal glycemic control have reduced the frequency of DR progression relative to earlier periods; however, DR still tends to worsen more rapidly during pregnancy than in nonpregnant individuals with diabetes.

These findings underscore the need for vigilant screening and meticulous management of glycemic levels throughout pregnancy.

### References:

1. Tomita, *et al. J Clin Med* 2021.

## Smoking is a risk factor for DR progression in patients with type 1 diabetes

- The risk of DR was significantly higher in smokers with type 1 diabetes, but significantly lower in smokers with type 2 diabetes compared to non-smokers.  
Type 1 diabetes, OR = 1.23 (95% CI:1.14-1.33)  
Type 2 diabetes, OR = 0.92 (95% CI:0.86-0.98)
- Different mechanisms may be involved in DR in type 1 and type 2 diabetes.

Cai X, et al. *Endocrine* 2018.

**R<sup>3</sup>i**  
Residual Risk Reduction Initiative

## Smoking is a risk factor for DR progression in patients with type 1 diabetes

A meta-analysis revealed that smoking significantly increases the risk of DR in patients with type 1 diabetes (OR = 1.23, 95% CI: 1.14–1.33), whereas it appears to modestly decrease the risk in type 2 diabetes (OR = 0.92, 95% CI: 0.86–0.98).

These divergent findings suggest that distinct pathophysiological mechanisms underlie DR in type 1 versus type 2 diabetes, underscoring the need for tailored risk assessments and interventions.

### References:

1. Cai X, et al. *Endocrine* 2018.



# Diagnosis of Diabetic Retinopathy

SECTION

4

**R<sup>3</sup>i**

Residual Risk Reduction Initiative

## Diagnosis 1

### ➤ Patient History and Systemic Assessment

- Assessment of diabetes duration, glycemic control (e.g., HbA1c level), blood pressure, lipid profile, and other systemic comorbidities (e.g., renal disease).

### ➤ Ophthalmic Examination

- Assessment of visual acuity (VA) and refractive status.
- Measurement of intraocular pressure (IOP) and anterior segment examination using a slit lamp.
- Dilated fundus examination with direct or indirect ophthalmoscopy to identify retinal pathology.

**R<sup>3</sup>i**

Retinal Risk Reduction Initiative

## Diagnosis 1

This slide outlines the initial steps in diagnosing diabetic retinopathy. First, a thorough **patient history and systemic assessment** is conducted, focusing on the duration of diabetes, glycemic control (e.g., HbA1c levels), blood pressure, lipid profile, and comorbidities such as renal disease.

Next, an **ophthalmic examination** is performed, which includes measuring visual acuity (VA), assessing refractive status, and checking intraocular pressure (IOP) using a slit lamp to evaluate the anterior segment.

Finally, a **dilated fundus examination**—via direct or indirect ophthalmoscopy—allows detailed visualization of the retina to identify any pathological changes associated with diabetic retinopathy.

## Diagnosis 2: Multimodal Imaging

- **Fundus Imaging:**  
Retinal findings (e.g., microaneurysms, hemorrhages, hard exudates, cotton-wool spots, venous beading, and neovascularization) through fundus photography (Ultra wide-field retinal imaging).
- **Optical Coherence Tomography (OCT):**  
Assesses macular edema and retinal layer integrity.
- **Optical Coherence Tomography Angiography (OCTA):**  
Provides a non-invasive visualization of retinal and choroidal microvasculature, enabling early detection of microvascular alterations and neovascular lesions without the need for dye injection.
- **Fundus Fluorescein Angiography (FFA):**  
Evaluates retinal vascular leakage, capillary non-perfusion, and neovascularization.

**R3i**  
Realist Risk Reduction Initiative

## Diagnosis 2: Multimodal Imaging


**Fundus photography** detects characteristic lesions such as microaneurysms, hemorrhages, exudates, cotton-wool spots, venous beading, and neovascularization.

**Optical Coherence Tomography (OCT)** provides cross-sectional images of the retina to evaluate macular edema and overall retinal structure.

**Optical Coherence Tomography Angiography (OCTA)** offers a dye-free visualization of the retinal and choroidal microvasculature, enabling early detection of neovascular lesions.

**Finally, Fundus Fluorescein Angiography (FFA)** uses fluorescein dye to identify vascular leakage, areas of non-perfusion, and neovascularization, thereby aiding in disease staging and management (but not necessary).

## Ultra wide-field retinal imaging device



Patient with moderate/severe NPDR

**R<sup>3</sup>i**


Retinal Risk Reduction Initiative

## Ultra wide-field retinal imaging device

Patient with moderate/severe NPDR. There are many hemorrhages and soft exudates.


The image was processed using Image Enhancement Software (Soft-MIEr, Logic and Design Inc. Tokyo, Japan).



**OCT angiography**

Non perfusion area (NPA)

Patient with Severe NPDR

**Wide angle OCT**

Diabetic macular edema (DME)

Patient with PDR+DME

**R3i**

Real-time Risk Reduction Initiative

**OCT angiography and wide angle OCT**

(Left) Approximately 80° wide-angle OCTA images. In conditions such as diabetic retinopathy, it can detect peripheral vascular abnormalities (including non-perfusion areas and neovascularization).

(Right) Swept source (SS) OCT enables high-resolution imaging from the vitreous to the retina, choroid, and scleral boundary.

## Fluorescein Angiography (FA)

Patient with PDR

Be mindful of potential allergic reactions to the contrast agent!



Non perfusion area (NPA)

Neovascularization (NV)

R<sup>3</sup>i

Retinal Risk Reduction Initiative


## Fluorescein Angiography (FA)

If OCTA cannot be performed, fluorescein angiography (FAG) should be conducted.

This slide shows a fluorescein fundus angiogram of diabetic retinopathy, obtained using a wide-field fundus camera. The dark regions between the retinal vessels represent areas of capillary occlusion, known as non-perfusion areas.

In contrast, the bright white patches indicate substantial fluorescein leakage, suggesting the presence of retinal neovascularization.

## Diagnosis 3: AI screening for DR



## Diagnosis 3: AI screening for DR

The IDx-DR system, which has received FDA approval, demonstrated a sensitivity of 96.8% and a specificity of 87.0%.

Another deep learning algorithm reported a sensitivity of 97.5% and a specificity of 93.4% for detecting referable DR.

These findings underscore the potential of AI-based methods to improve DR screening efficiency and accuracy, ultimately facilitating earlier intervention and better visual outcomes.

### References:

- 1: Abramoff D, *Invest Ophthalmol Vis Sci* 2016.
- 2: Gulshan V, *et al. JAMA* 2016.


## Complications of Diabetic Retinopathy

### Vitreous Hemorrhage

- Occurs due to the rupture of fragile neovascular vessels, resulting in sudden and often severe vision loss.
- May require surgical intervention, such as pars plana vitrectomy, to clear the hemorrhage.

### Tractional Retinal Detachment

- Results from fibrovascular proliferation and contraction of epiretinal membranes.
- May lead to retinal detachment, further compromising visual function.



Tractional Retinal Detachment

R<sup>3</sup>i

Retinal Risk Reduction Initiative

## Complications of Diabetic Retinopathy

Vitreous hemorrhage arises from the rupture of fragile neovascular vessels, leading to sudden and often severe vision loss. Tractional retinal detachment occurs when fibrovascular proliferation within the preretinal membranes exerts traction on the retina, compromising visual function.

Neovascular glaucoma develops as newly formed vessels in the iris or angle obstruct aqueous outflow, causing intraocular pressure to rise and vision to deteriorate rapidly. Diabetic macular edema (DME) results from blood–retinal barrier breakdown and increased vascular permeability, leading to fluid accumulation in the macula and subsequent impairment of central vision.


If left untreated, each of these complications can cause irreversible vision loss, underscoring the importance of early detection and timely intervention.

## Neovascular Glaucoma

- Occurs when neovascularization extends to the iris and the anterior chamber angle.
- Leads to secondary angle-closure glaucoma due to impaired aqueous humor outflow, leading to elevated intraocular pressure.

### Diabetic Macular Edema (DME)

- Characterized by fluid accumulation in the macula due to capillary leakage and blood-retinal barrier breakdown.
- Represents the primary cause of central vision loss in patients with DR.



Tomita Y, et al. *Jpn J Ophthalmol* 2010.

**R<sup>3</sup>i**  
Realist Risk Reduction Initiative

## Neovascular Glaucoma

## Other ocular complications of Diabetes Mellitus

### Cataract

- The incidence of cataracts in diabetic patients under the age of 65 is 3 to 4 times higher than in non-diabetic patients.<sup>1</sup>
- Cataracts can develop at a younger age in diabetic patients.<sup>2</sup>
- The commonest types of cataracts in diabetic patients are cortical opacities and posterior capsular opacities.

### Diabetic Keratopathy

- Classified into diabetic corneal epithelial and endothelial disorder.
- Corneal sensitivity significantly decreases as the severity of DR progresses.<sup>3</sup>

1. Ederer F, et al. *Am J Ophthalmol*. 1981.
2. Mrugacz M, et al. *Int J mol Sci* 2023.
3. Saito J, et al. *Cornea* 2003.
4. Dogru M, et al. *Ophthalmology* 2001.

**R<sup>3</sup>i**  
Retinal Risk Reduction Initiative

## Other ocular complications of Diabetes Mellitus

### References:

1. Ederer F, et al. *Am J Ophthalmol*. 1981.
2. Mrugacz M, et al. *Int J mol Sci* 2023.
3. Saito J, et al. *Cornea* 2003.
4. Dogru M, et al. *Ophthalmology* 2001.


# Treatment and Management of Diabetic Retinopathy

SECTION

5

**R<sup>3</sup>i**

Residual Risk Reduction Initiative



### A strategy for the treatment of DR

A flowchart illustrating the suggested treatment strategy for diabetic retinopathy (DR) without macular edema.

DR is classified into non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR). NPDR is further divided into three subcategories: mild, moderate, and severe.

Maintaining optimal glucose, lipid levels, and blood pressure is crucial at all stages.



#### Abbreviations:

NPDR: non-proliferative diabetic retinopathy, DME: diabetic macular edema, TRP: targeted retinal photocoagulation, FA: fluorescein angiography, NPA: non-perfusion area, NVG: neovascular glaucoma.



## Laser Treatment for DR

- Pan-Retinal Photocoagulation (PRP)
  - Conventional laser
  - Pattern Scan Laser
- Targeted Retinal Photocoagulation (TRP)



PRP by conventional laser

Non perfusion area (NPA)

**R<sup>3</sup>i**

Retinoid Risk Reduction Initiative

## Laser Treatment for DR

### Pan-Retinal Photocoagulation (PRP)

- The main treatment for DR, reducing retinal neovascularization and the risk of vision loss.
- Recommended for severe NPDR to early PDR, based on ETDRS guidelines.
- Reduces the risk of severe vision loss by 50%
- Complications include peripheral visual field loss, delayed dark adaptation, atrophic creep.

### Pattern Scan Laser

- Designed to minimize the side effects of PRP.
- Benefits include reduced nerve fiber layer damage, less pain, and shorter procedure time.

### Targeted Retinal Photocoagulation (TRP) & NAVILAS

- A selective treatment for NPDR that slows the progression to PDR.
- Requires OCTA or fluorescein angiography (FA) to identify non-perfusion areas (NPA).

### References:

1. Tomita, *et al.* *J Clin Med* 2021.

## Vitrectomy for Proliferative Diabetic Retinopathy (PDR)

### ► Indications:

Indicated for vitreous hemorrhage or tractional retinal detachment (TRD) involving or threatening the macula. Delayed intervention for macular detachment may result in irreversible vision loss.

► Advancements: Small-gauge vitrectomy (23-, 25-, 27-gauge), wide-angle viewing systems, and 3D heads-up surgery enhance surgical safety and visualization. Early vitrectomy is recommended for severe fibrovascular proliferation, extensive prior PRP, or media opacities. Preoperative anti-VEGF therapy improves surgical outcomes in some cases.

► Postoperative Issues: Re-bleeding, though reduced with small-gauge vitrectomy. Cataract formation in phakic patients. Endophthalmitis. Retinal detachment, glaucoma, or ischemia.

Tomita, *et al.* *J Clin Med* 2021.

**R3i**  
Retinal Risk Reduction Initiative

## Vitrectomy for Proliferative Diabetic Retinopathy (PDR)

Vitrectomy is indicated for proliferative diabetic retinopathy (PDR) in cases of vitreous hemorrhage or tractional retinal detachment (TRD) involving or threatening the macula. Delayed intervention for macular detachment can result in permanent vision loss.

Recent advances include small-gauge vitrectomy (23-, 25-, or 27-gauge) and wide-angle viewing systems (e.g., Resight®), which enhance surgical safety and visualization. Early vitrectomy is recommended for severe fibrovascular proliferation, extensive prior PRP, or media opacities, and preoperative anti-VEGF therapy may improve surgical outcomes.

Potential complications include retinal detachment, re-bleeding, glaucoma, ischemia, cataract progression, and endophthalmitis. Despite these risks, timely vitrectomy often preserves or improves visual function in patients with advanced PDR.

### References:

1. Tomita, *et al.* *J Clin Med* 2021.

### 3D heads-up surgery



#### Advantages

1. Improved Ergonomics
2. Digital Image Enhancement
3. Better Teaching and Collaboration
4. Easy Integration with Other Systems

### Conventional microscopic surgery



#### Disadvantages

1. Possible Image Lag
2. Requires Space in the Operating Room
3. Higher Cost and Learning Curve

**R<sup>3</sup>i**  
Realized Risk Reduction Initiative

## 3D heads-up surgery and conventional microscopic surgery

### 3D heads up surgery

#### *Advantages*

1. Improved Ergonomics: Surgeons can operate while viewing a 3D monitor at a comfortable angle, reducing neck and back strain.
2. Digital Image Enhancement: The system can adjust color balance, contrast, and magnification, potentially improving visualization of fine structures.
3. Better Teaching and Collaboration: Everyone in the operating room sees the same high-resolution, stereoscopic image on a large monitor, enhancing training and teamwork.
4. Easy Integration with Other Systems: Digital output facilitates recording, playback, and analysis, useful for documentation and educational purposes.

#### *Disadvantages*

1. Possible Image Lag: High-resolution 3D visualization may introduce slight delays, which can affect surgical precision.
2. Requires space in the operation room: The monitor is quite huge.
3. Higher Cost and Learning Curve: The equipment is expensive, and surgeons may require additional training to become proficient.

## Anti-VEGF treatment for PDR

### ➤ Efficacy:

- Protocol S; Ranibizumab provided better visual acuity outcomes compared to PRP<sup>1</sup>.
- In the 5-year follow-up results, the long-term safety and efficacy of ranibizumab were confirmed, with ranibizumab maintaining superiority over PRP in terms of visual acuity and visual field preservation<sup>2</sup>.
- CLARITY trial: Aflibercept was effective for PDR without DME<sup>3</sup>.

### ➤ Limitations:

Frequent follow-up visits are essential for maintaining disease control. Non-adherence to treatment intervals can lead to worse outcomes, including recurrent neovascular activity.

### ➤ Considerations:

- Higher treatment cost compared to PRP.
- Importance of long-term compliance with anti-VEGF therapy to sustain visual gains in PDR.

### Benefits over PRP<sup>4</sup>:

- Less peripheral visual field loss
- Lower incidence of DME
- Reduced need for vitrectomy

1. DRCR.net Protocol S, *JAMA* 2015. 2. Bressler NM, *et al. JAMA Ophthalmology* 2019.  
3. Clarity Study Group, *Lancet* 2017. 4. Tomita, *et al. J Clin Med* 2021.

**R3i**  
Retinal Risk Reduction Initiative

## Anti-VEGF treatment for PDR


Anti-VEGF therapy for proliferative diabetic retinopathy (PDR) has demonstrated comparable or superior efficacy to panretinal photocoagulation (PRP).

In Protocol S, intravitreal ranibizumab showed improved visual outcomes, reduced peripheral visual field loss, and a lower incidence of diabetic macular edema (DME) compared to PRP.

The CLARITY trial found that aflibercept was also effective for PDR, even in the absence of DME. Although anti-VEGF therapy carries the advantages of fewer visual field defects and a reduced need for vitrectomy, its limitations include higher cost and the need for frequent follow-up. Adherence to treatment intervals is essential for maintaining control of neovascular activity.

### References:

1. DRCR.net Protocol S, *JAMA* 2015.
2. Bressler NM, *et al. JAMA Ophthalmology* 2019.
3. Clarity Study Group, *Lancet* 2017.
4. Tomita, *et al. J Clin Med* 2021.



### Strategy for treatment of diabetic macular edema (DME)

A flowchart illustrating the suggested treatment strategy for diabetic macular edema (DME). The treatment strategy is determined based on whether the edema involves the fovea.

Maintaining optimal glucose, lipid, and blood pressure levels is crucial at all stages.

#### Abbreviations:

SDM: subthreshold diode laser micropulse photocoagulation;

DME: diabetic macular edema.

#### References:

1. Tomita, et al. *J Clin Med* 2021.

## Laser therapy for diabetic macular edema (DME)

### Focal/Grid Laser


ETDRS demonstrated better outcomes with focal/grid laser compared to natural course in severe DME.

**Indication:** DME not involving the fovea, allowing for fewer hospital visits.

**Complications:** Paracentral dark spots and atrophic creep in chronic cases. The modified ETDRS Laser (DRCR net, 2007) was introduced to minimize damage by selectively targeting capillary aneurysms with a less invasive approach.

### However ...

- Possible transient initial decrease in central vision
- Paracentral scotomas if laser burns occur close to the fovea, especially large or confluent burns
- Permanent central scotoma from inadvertent foveal burns
- Expansion of laser scar area (over many years)
- Choroidal neovascularization and subretinal fibrosis



Lim JI, *et al. Ophthalmology* 2025. Luttrull JK, *et al. Current Diabetes Reviews* 2012.

**R<sup>3</sup>i**  
Retinoid Risk Reduction Initiative

## Laser therapy for diabetic macular edema (DME)

Focal or grid laser therapy (ETDRS-based) is effective for DME that does not involve the fovea, stabilizing or improving vision with fewer hospital visits.

Modified protocols reduce laser-induced scotomas and atrophic creep.

### References:

1. Lim JI, *et al. Ophthalmology* 2025.
2. Luttrull JK, *et al. Current Diabetes Reviews* 2012.


## Subthreshold Diode Micropulse Laser (SDM)

A non-damaging laser therapy that applies heat to the retinal pigment epithelium (RPE) without causing cell death

**Indications:** Localized edema outside the fovea. Mild macular edema involving the fovea.

**Benefits:** Effective as monotherapy for mild DME, with randomized trials demonstrating superiority over the modified ETDRS laser.

For severe DME, combination therapy with anti-VEGF is recommended.



Tomita, et al. *J Clin Med* 2021. Luttrull JK, et al. *Current Diabetes Reviews* 2012.

**R<sup>3</sup>i**  
Retinoid Risk Reduction Initiative

## Subthreshold Diode Micropulse Laser (SDM)

Subthreshold diode micropulse laser (SDM) targets the retinal pigment epithelium without damaging the neural retina, making it suitable for mild DME. For severe DME, combination therapy with anti-VEGF agents is recommended.

A–F. This figure illustrates the ‘Effective Surface Area’ achieved by various retinal laser treatment modalities for retinal vascular disease.

The vermillion (red) regions represent retina untouched by the laser, whereas the brown areas mark retinal tissue ablated by the laser and thus rendered inactive with respect to extracellular cytokine production.

The yellow regions indicate retina that is laser-affected but not destroyed, retaining the potential to support therapeutic outcomes through laser-induced modulation or normalization of cytokine expression.

PASCAL (pattern scanning laser), MP (diode micropulse laser), SDM (subthreshold/subvisible diode micropulse laser).

### References:

1. Tomita, et al. *J Clin Med* 2021.
2. Luttrull JK, et al. *Current Diabetes Reviews* 2012.

## Anti-vascular endothelial growth factor (VEGF) treatment for DME

Effective for DME involving the central macula.

Aflibercept (2mg, 8mg, ranibizumab, bevacizumab, faricimab, brolucizumab, and biosimilars).

Multiple injections required;  
Combining with laser may reduce frequency.

### Risks:

Increased intraocular pressure (IOP), endophthalmitis, cataract formation, retinal damage, and systemic drug diffusion.

Tomita, *et al.* J Clin Med 2021.

**R<sup>3</sup>i**  
Retinal Risk Reduction Initiative

## Anti-vascular endothelial growth factor (VEGF) treatment for DME

Anti-VEGF agents (aflibercept, ranibizumab, bevacizumab, faricimab, brolucizumab) are effective for center-involved diabetic macular edema, though multiple injections are typically required.

Combination with laser therapy may reduce injection frequency. Potential risks include elevated intraocular pressure, endophthalmitis, cataract formation, retinal damage, and systemic drug exposure.

Treatment selection should consider overall patient health, visual acuity, and central retinal thickness.

### References:

1. Tomita, *et al.* J Clin Med 2021.



## Anti-VEGF therapy

- Aflibercept (2mg, 8mg)
- Bevacizumab
- Ranibizumab
- Brolucizumab
- Faricimab
- Biosimilars


Drug approvals vary among countries

**R<sup>3</sup>i**

Realised Risk Reduction Initiative

## Anti-VEGF therapy

Multiple, high-quality clinical trials and systematic reviews have demonstrated that anti-VEGF therapy is more effective in improving vision in eyes with center involved (CI)-DME than monotherapy with focal laser surgery treatment, thus supplanting focal laser surgery as the first-line therapy.



### Anti-VEGF therapy

This slide shows a representative case of a 70-year-old male with diabetic macular edema (DME). At baseline, his best-corrected visual acuity (VA) was 0.7 and central macular thickness (CMT) measured 491  $\mu$ m.

Two months after anti-VEGF therapy with aflibercept (8 mg), VA improved to 0.52, and CMT decreased to 310  $\mu$ m.

These findings demonstrate both functional (VA) and structural (CMT) improvements, underscoring the effectiveness of anti-VEGF therapy in managing DME.

## Steroid treatment for DME

Used for diffuse DME with anti-inflammatory & anti-angiogenic effects.

### Administration:

IVTA, STTA, DEX implant, fluocinolone implant.

### Treatment Options:

IVTA: Effective but short duration, requires multiple injections.

STTA: Less effective but lower IOP risk, useful for anti-VEGF-resistant DME.

DEX Implant: Longer duration, effective but no added visual benefit over anti-VEGF.

Fluocinolone Implant: Longest duration, useful for refractory DME.

### Risks:

Glaucoma, cataract progression, and noninfectious endophthalmitis (0.1%–7.3%).

Tomita, *et al.* *J Clin Med* 2021.

**R<sup>3</sup>i**  
Residual Risk Reduction Initiative

## Steroid treatment for DME

Steroid therapy for diabetic macular edema (DME) provides anti-inflammatory and anti-angiogenic effects, particularly for diffuse DME.

Common delivery methods include intravitreal triamcinolone (IVTA), sub-Tenon triamcinolone (STTA), and dexamethasone or fluocinolone implants.

Although these treatments can be effective—especially in refractory or anti-VEGF-resistant cases—they carry risks of elevated intraocular pressure, cataract progression, and noninfectious endophthalmitis.

Careful patient selection and close monitoring are essential to minimize complications.

### References:

1. Tomita, *et al.* *J Clin Med* 2021.

## Vitrectomy for DME

### Indications:

Indicated for epiretinal membrane (ERM), vitreomacular traction (VMT), or cases where other treatments (anti-VEGF, steroids, laser therapy) have failed. Internal limiting membrane (ILM) peeling prevents recurrence.

### Outcomes:

Comparable to anti-VEGF, greater CMT reduction than IVTA, but no significant visual function difference long-term.

### Considerations:

Carries the same risks as other vitrectomy procedures.

Tomita, *et al.* *J Clin Med* 2021.

**R3i**  
Retinal Risk Reduction Initiative

## Vitrectomy for DME

Vitrectomy for diabetic macular edema (DME) is primarily indicated when mechanical traction from an epiretinal membrane or vitreomacular traction is present, or when medical therapies (e.g., anti-VEGF, steroids) and laser treatment have failed.

In such cases, pars plana vitrectomy (PPV) can relieve traction and reduce central macular thickness, often with inner limiting membrane (ILM) peeling to prevent recurrence.

While vitrectomy typically achieves rapid anatomical improvement, long-term visual outcomes may not significantly exceed those of intravitreal injections.


Patient selection is key, and standard surgical risks—such as cataract progression, retinal breaks, and endophthalmitis—must be considered.

### References:

1. Tomita, *et al.* *J Clin Med* 2021.

## Cystotomy for refractory cystoid macular edema secondary to DR

- In a study of 22 eyes with diabetic macular edema (DME), cystotomy performed during pars plana vitrectomy (PPV) led to visual improvement or stabilization in 90% of cases.<sup>1</sup>
- In refractory DME with cystoid macular edema (CME), anterior cyst wall resection was performed, resulting in visual improvement maintained for up to 12 months postoperatively.<sup>2</sup>



1. Tach N, et al. *Doc Ophthalmol* 1999.  
2. Imai H, et al. *Retina* 2021.

**R<sup>3</sup>i**  
Residual Risk Reduction Initiative

## Cystotomy for refractory cystoid macular edema secondary to DR

This procedure is performed for refractory DME that does not respond to anti-VEGF therapy, laser treatment, or conventional vitrectomy.

In some cases, an additional procedure to remove fibrinogen may be included.

Although current reports are retrospective and based on a small number of cases, the effectiveness is promising, and further prospective studies are warranted.

### References:

1. Tach N, et al. *Doc Ophthalmol* 1999.
2. Imai H, et al. *Retina* 2021.



# **Prevention of Diabetic Retinopathy and Future Treatments**

**SECTION**

**6**


**R<sup>3</sup>i**

Residual Risk Reduction Initiative

## Maintaining good glycemic control is essential

Maintaining HbA1c levels below 7.0% is effective in preventing the onset and progression of DR in type 2 diabetes mellitus (T2DM), as demonstrated in the Kumamoto Study<sup>1</sup>

Relationship between HbA1c levels and the progression of DR (UKPDS)<sup>2</sup>



CIT: Conventional insulin injection therapy; MIT: Multiple insulin injection therapy.

1: Ohkubo Y, et al. *Diabetes Res Clin Pract* 1995. 2: UKPDS 50, *Diabetologia* 2001.

**R3i**  
Retinal Risk Reduction Initiative

## Maintaining good glycemic control is essential

It is well known that long-term glycemic control suppresses the progression of diabetic retinopathy (DR). One of the key studies supporting this evidence is the *Kumamoto Study* from Japan.

This study demonstrated that, in patients with type 2 diabetes mellitus (T2DM), an intensive insulin therapy group maintaining HbA1c below 7% had a significantly lower risk of DR progression compared to those receiving conventional therapy.

Additionally, the study reported a significant reduction in major vascular events. Furthermore, a report from the UK also showed that an increase in HbA1c levels is associated with a higher risk of DR progression.

The relationship between blood glucose levels and DR is well established, and it is generally accepted that the lower the HbA1c level, the lower the risk of both the onset and progression of DR.

### References:

1. Ohkubo Y, et al. *Diabetes Res Clin Pract* 1995.
2. UKPDS 50, *Diabetologia* 2001.



## Which treatments are effective in preventing the onset of DR

Drug	Direct Drug Comparisons/participants (n/N)	Odds ratio (95% CI)	
		Pairwise meta-analysis	Network meta-analysis
DPP-4i	443/39 717	1.27 (1.05, 1.53)	1.20 (0.87, 1.65)
GLP-1RA	846/37 387	1.15 (0.93, 1.43)	1.19 (0.94, 1.52)
SGLT2 inhibitors	124/7962	0.78 (0.54, 1.12)	0.79 (0.49, 1.28)
Sulfonylureas	16/408	2.37 (0.53, 10.59)	1.67 (1.01, 2.76)
Thiazolidinediones	20/392	2.44 (0.70, 8.50)	1.50 (0.84, 2.67)
Metformin			1.70 (0.80, 3.61)
$\alpha$ -glucosidase inhibitors			10.00 (0.38, 260.64)
Glinides			3.37 (0.06, 178.08)
Insulin			1.25 (0.73, 2.15)

- Meta-analysis of 36 studies.
- Over 100,000 participants.
- Onset of DR-related events.

CI: Confidence interval; n/N: number of events/number of patients;  
SGLT2 inhibitors: Sodium-Glucose Cotransporter-2 Inhibitors.  
Tang H, et al. *Diabetes, Obesity and Metabolism* 2018.

**R<sup>3</sup>i**  
Realist Risk Reduction Initiatives

## Which treatments are effective in preventing the onset of DR


This **meta-analysis of 36 studies with over 100,000 participants** examines the impact of glucose-lowering drugs on **diabetic retinopathy (DR) onset**.

- **SGLT2 inhibitors** show a potential reduction in DR risk (**OR: 0.78–0.79**), but the effect is not statistically significant.
- **Sulfonylureas and thiazolidinediones** may increase DR risk, while **DPP-4 inhibitors, GLP-1 receptor agonists, and insulin** show no significant impact.
- Findings suggest **SGLT2 inhibitors might be beneficial**, but further research is needed to confirm their protective role.

### References:

1. Tang H, et al. *Diabetes, Obesity and Metabolism* 2018.

## SGLT2-inhibitors are associated with a lower risk of developing DR compared to DPP4-inhibitors, pioglitazone, and sulfonylureas



## SGLT2-inhibitors are associated with a lower risk of developing DR compared to DPP4-inhibitors, pioglitazone, and sulfonylureas

Yen *et al.* analyzed data from **3.54 million T2DM patients** in Taiwan's NHI database, showing that **SGLT2 inhibitors lower the risk of sight-threatening DR** compared to DPP-4 inhibitors, pioglitazone, and sulfonylureas.

### Proposed Mechanisms for DR Risk Reduction:

1. Improved **retinal neurovascular coupling and microcirculation**
2. **Suppression of endothelial cell apoptosis**

### Study Strengths:

- **Large-scale population data** (95% coverage in Taiwan) minimizing selection bias
- **Robust statistical power** with a large DR case count
- **Sufficient follow-up period** to track DR development


### Limitations:

- **Lack of lifestyle factors** (family history, smoking, alcohol, activity)
- **Limited retinal exam data** (fundus, FA, OCT)
- **Ethnic generalizability concerns** (mainly Taiwanese cohort)

These findings suggest **SGLT2 inhibitors may help prevent DR**, but further global studies are needed.

**Abbreviations:** DPP4i: Dipeptidyl Peptidase-4 Inhibitor, SGLT2i: Sodium-Glucose Cotransporter 2 Inhibitor

**References:** 1. Yen Fu S, *et al. JAMA Net Open* 2023.



## SGLT2-inhibitors & DME

A real-world analysis was conducted using a database from JMDC (Japan Medical Data Center), which aggregates health insurance claims and medical checkup data. This study extracted data with type 2 diabetes who had received anti-VEGF therapy for DME and divided them into two groups based on SGLT2 inhibitor use.

The analysis revealed that patients using SGLT2 inhibitors required fewer anti-VEGF injections, suggesting a potential role for these drugs as a novel treatment option for DME. They also conducted a randomized clinical trial evaluating the use of ranibizumab in combination with luseogliflozin for diabetic macular edema (DME) in patients with type 2 diabetes.

Readministration rates were decreased significantly at the fourth injection in the SGLT2i group ( $p = 0.030$ , hazard ratio: 0.45, 95% CI 0.22–0.92) (upper right). Additionally, fellow eyes in the SGLT2i group showed fewer injections compared with those in the SU group ( $1.3 \pm 0.6$  vs.  $3.4 \pm 0.8$ ,  $p = 0.016$ ) (lower right).


### References:

1. Ishibashi R, et al. *Diabetes Obes Metab* 2023.
2. Ishibashi R, et al. *Diabetes Obes Metab* 2025.


## Candesartan: Angiotensin II receptor blocker (ARB)

Candesartan was effective in preventing the onset of DR in patients with type 1 diabetes mellitus (DIRECT-1)<sup>1</sup>

Candesartan was effective in promoting the regression of DR in patients with type 2 diabetes mellitus (DIRECT-2)<sup>2</sup>



No. at risk							
Placebo	710	663	630	587	419	109	1
Candesartan	711	651	615	587	422	108	1



No. at risk							
Placebo	954	812	760	713	510	93	1
Candesartan	951	811	755	692	492	100	0

1: Chaturvedi N, *et al. Lancet* 2008. 2: Sjolie AK, *et al. Lancet* 2008.

**R3i**  
Retinal Risk Reduction Initiative

## Candesartan: Angiotensin II receptor blocker (ARB)

This slide presents findings from the DIRECT studies, which examined the effects of candesartan, an angiotensin II receptor blocker (ARB), on diabetic retinopathy (DR). The results indicate:

- **DIRECT-1 (Left graph):** In patients with type 1 diabetes mellitus, candesartan was effective in preventing the onset of DR compared to placebo.
- **DIRECT-2 (Right graph):** In patients with type 2 diabetes mellitus, candesartan promoted the regression of DR, suggesting a potential role in reversing retinal damage.


These findings suggest that candesartan may have both preventative and therapeutic benefits in diabetic retinopathy without significant adverse effects compared to placebo.

### References:

1. Chaturvedi N, *et al. Lancet* 2008.
2. Sjolie AK, *et al. Lancet* 2008.

## Meta-analysis

A significant 23% reduction in incidence of DR was observed in normotensive patients treated with renin-angiotensin system (RAS) inhibitors (RR: 0.77, 95% CI: 0.66-0.90,  $p=0.001$ )



## Meta-analysis


This meta-analysis evaluates the effect of renin-angiotensin system (RAS) inhibitors on diabetic retinopathy (DR) incidence. The results indicate a significant 23% reduction in DR incidence among normotensive patients treated with RAS inhibitors (RR: 0.77, 95% CI: 0.66–0.90,  $p=0.001$ ). However, in hypertensive patients, no significant effect on DR incidence was observed.

These findings suggest a potential DR-preventive effect of RAS inhibitors independent of blood pressure reduction. These findings suggest that RAS inhibition suppresses the progression of DR through mechanisms beyond blood pressure control.

### References:

1. Wang Bin, *et al.* *Lancet Diabetes Endocrinol* 2015.

## Effectiveness of antihypertensive drugs in DR prevention: ACE inhibitors > ARBs > Calcium channel blockers > Beta-blockers > Placebo



Blood pressure management is crucial for preventing onset, progression, and potential regression of DR

Wang Bin, et al. *Lancet Diabetes Endocrinol* 2015.

R<sup>3</sup>i  
Rational Risk Reduction Initiative

## Effectiveness of antihypertensive drugs in DR prevention: ACE inhibitors > ARBs > Calcium channel blockers > Beta-blockers > Placebo


This slide presents a meta-analysis and network meta-analysis evaluating the effectiveness of antihypertensive drugs in preventing diabetic retinopathy (DR). Key findings include:

1. **ACE inhibitors and ARBs** have been consistently shown to reduce the incidence and progression of DR.
2. **Network meta-analysis** suggests that **ACE inhibitors are the most effective** in DR prevention, followed by ARBs, calcium channel blockers, and beta-blockers.
3. **Blood pressure management is crucial** not only for preventing DR onset but also for its progression and potential regression.
4. **Network meta-analysis methodology** allows for both direct and indirect comparisons between different treatment options, providing a comprehensive evaluation of their relative efficacy.

These results highlight the importance of **ACE inhibitors and ARBs** in DR management, supporting their use as first-line antihypertensive agents for diabetic patients at risk of DR.

### References:

1. Wang Bin, et al. *Lancet Diabetes Endocrinol* 2015.



## Initiating dialysis may improve diabetic macular edema (DME)

This study from J-CREST (Japan) investigated the impact of initiating dialysis on diabetic macular edema (DME). A retrospective analysis of 132 eyes from 70 patients over one year demonstrated improvements in visual acuity and a significant reduction in central retinal thickness (CRT) after dialysis initiation. Notably, the improvement rate was higher in patients with the serous retinal detachment (SRD) type of DME.


The findings suggest that systemic factors, particularly renal function and fluid regulation via dialysis, play a crucial role in DME pathophysiology.

These results highlight the strong link between kidney function and diabetic retinopathy.

### References:

1. Takamura Y, et al. *J-Crest Sci Rep* 2020.

## Statins may reduce the risk of DR progression



- Propensity score matching
- 62,716 participants
- Statin users had a 30% lower risk of developing DR (HR: 0.70, 95% CI: 0.62-0.80,  $p<0.0001$ )

Nielsen, et al. *Lancet Diabetes Endocrinol* 2014.

**R3i**  
Residual Risk Reduction Initiative

## Statins may reduce the risk of DR progression


This slide suggests that statin use may reduce the risk of diabetic retinopathy (DR) progression. Based on a Danish registry study using propensity score matching, the analysis showed that statin users had a 30–40% lower risk of developing DR (HR: 0.70, 95% CI: 0.62-0.80,  $p<0.0001$ ).

This study suggests that statins may contribute to DR prevention and progression delay, potentially due to their anti-inflammatory and vascular protective effects.

### References:

1. Nielsen, et al. *Lancet Diabetes Endocrinol* 2014.





## Statins reduce the onset and progression of DR

This figure illustrates the cumulative incidence of diabetic retinopathy (DR) in patients with type 2 diabetes and dyslipidemia, comparing statin users with non-users over a 15-year follow-up period. Data were derived from a cohort of 37,894 individuals using propensity score matching. Statin use was associated with a significant reduction in the onset and progression of DR, as well as in the need for retinal laser treatment.

**Figure A** shows the cumulative incidence of any diabetic retinopathy. Statin users had a significantly lower incidence compared to non-users (Hazard Ratio [HR], 0.86; 95% Confidence Interval [CI], 0.81–0.91;  $P < 0.001$ ).

**Figure B** demonstrates the incidence of nonproliferative diabetic retinopathy. Statin therapy was associated with a modest but statistically significant reduction in risk (HR, 0.92; 95% CI, 0.86–0.99;  $P = 0.03$ ).

**Figure C** presents the incidence of proliferative diabetic retinopathy. Statin users showed a markedly lower risk compared to non-users (HR, 0.64; 95% CI, 0.58–0.70;  $P < 0.001$ ), indicating a robust protective effect against severe retinal disease.

**Figure D** shows the cumulative incidence of retinal laser treatment, an indicator of advanced diabetic retinopathy. Statin use was associated with a significantly reduced need for such intervention (HR, 0.71; 95% CI, 0.65–0.77;  $P < 0.001$ ).

These findings suggest that statins not only reduce the risk of cardiovascular events in patients with diabetes but may also confer a protective effect against the development and progression of diabetic retinopathy.

**References:** 1. Kang, et al. *JAMA ophthalmol* 2019.

A systematic review and meta-analysis found that statins were associated with reduced incidence of DR, such as laser therapy, intravitreal injections, and vitrectomy<sup>1</sup>

However, a database study found no significant effect of statins on the onset of DR or DME (USA)<sup>2</sup>

Variable	Diabetic Retinopathy		NPDR		PDR		DME		Vitreous Heme		TRD	
	Hazard Ratio (95% CI)	P-Value	Hazard Ratio (95% CI)	P-Value	Hazard Ratio (95% CI)	P-Value	Hazard Ratio (95% CI)	P-Value	Hazard Ratio (95% CI)	P-Value	Hazard Ratio (95% CI)	P-Value
Statin	1.03 (0.99, 1.07)	0.13	1.06 (1.01, 1.11)	0.02	0.89 (0.79, 1.02)	0.09	0.94 (0.86, 1.03)	0.21	1.00 (0.86, 1.16)	0.99	1.11 (0.89, 1.38)	0.36

- Database study (United States)
- Diabetes (no DR) and dyslipidemia
- 66,617 statin users / 83,365 non-statin users

1: Panata, et al. *Eur J Ophthalmol* 2021. 2: Meer, et al. *Pharmacoepidemiol Drug Saf* 2022.

R<sup>3</sup>i

Retinal Risk Reduction Initiative

A systematic review and meta-analysis found that statins were associated with reduced incidence of DR, such as laser therapy, intravitreal injections, and vitrectomy


A systematic review and meta-analysis by Panata *et al. Eur. J. Ophthalmol* 2021, demonstrated that statin use was associated with a reduced incidence of diabetic retinopathy (DR) and its complications, including the need for laser photocoagulation, intravitreal injections, and vitrectomy. These findings support a potential protective role of statins in DR progression.

However, a large-scale database study conducted in the United States, Meer *et al. Pharmacoepidemiol Drug Saf* 2022, reported no significant association between statin use and the onset or severity of DR or diabetic macular edema (DME). The study included 66,617 statin users and 83,365 non-users, all with diabetes and dyslipidemia but no prior history of DR at baseline.

As shown in the table, the hazard ratio (HR) for developing any diabetic retinopathy among statin users was 1.03 (95% CI, 0.99–1.07; P = 0.13), indicating no significant difference. While a statistically significant increase was observed for nonproliferative DR (HR, 1.06; 95% CI, 1.01–1.11; P = 0.02), no significant associations were found for proliferative DR, DME, vitreous hemorrhage, or tractional retinal detachment.

These discrepant findings highlight the need for further research to clarify the role of statins in DR prevention, particularly considering differences in study design, population characteristics, and confounding factors.

**References:** 1. Panata, *et al. Eur J Ophthalmol* 2021.  
2. Meer, *et al. Pharmacoepidemiol Drug Saf* 2022.



## Fenofibrate reduces the progression of DR

Large-scale clinical trials, including the FIELD and ACCORD studies, have demonstrated that fenofibrate reduces the need for laser treatment and slows the progression of diabetic retinopathy (DR), independent of statin use. These findings led to its approval in Australia as a preventive drug for DR.

Fenofibrate, a fibrate-class lipid-lowering agent, has gained sustained attention due to its potential protective effects on DR. The FIELD study (2007) first highlighted its benefits, showing that fenofibrate reduced the risk of laser treatments for DR as a secondary outcome. However, variations in statin use among participants raised concerns.

The ACCORD-EYE study was conducted to address this issue, specifically analyzing fenofibrate's effects in patients already on statin therapy. The results confirmed that fenofibrate independently suppressed DR progression.


These findings have since spurred extensive research into the underlying mechanisms using animal and cellular models. As a result, fenofibrate is now prescribed in Australia for DR prevention.

### References:

1. Keech AC, et al. *Lancet* 2007.
2. Chew EY, *N Engl J Med* 2015.

LENS trial: Fenofibrate reduced the progression of DR

The LENS (Lowering Events in Non-proliferative retinopathy in Scotland) trial




LENS trial: Fenofibrate reduced the progression of DR

Recently, clinical trials specifically designed to investigate the ocular effects of fenofibrate have also demonstrated that fenofibrate reduced the progression of DR.

However it also showed that fenofibrate reduced renal function, so it's challenging to use it for DR patients with dysfunction of kidney.

References:

1. Preiss, et al. NEJM Evid 2024.



## PPAR $\alpha$


### Peroxisome Proliferator-Activated Receptor $\alpha$

Fenofibrate activates peroxisome proliferator-activated receptor alpha (PPAR $\alpha$ ), which is expressed in many tissues. It lowers serum triglycerides and increases HDL cholesterol. Several studies have demonstrated that fenofibrate reduces inflammation and vascular permeability in the retinas of diabetic mouse models.

Fenofibrate also exerts anti-angiogenic effects by suppressing VEGF, a key mediator of pathological neovascularization in the retina. Previously, our group showed that fenofibrate protected the retina from ischemia by downregulating hypoxia-inducible factor-1 (HIF-1), a key regulator of VEGF.

#### References:

1. Abvouwer SF, *Diabetes* 2013.
2. Chen Y, *et al. Diabetes* 2013.
3. Lee D\*, Tomita Y\*, *et al. Pharmaceuticals* 2021.



## SPPARM $\alpha$


### (Selective Peroxisome Proliferator-Activated Receptor $\alpha$ Modulator)

This slide highlights **pemafibrate**, a **selective PPAR $\alpha$  modulator (SPPARM $\alpha$ )** approved in Japan for dyslipidemia management. Its unique molecular structure enables it to activate PPAR $\alpha$  up to **10,000 times more potently** than fenofibrate.

As a result, pemafibrate **lowers serum triglycerides and increases HDL cholesterol** while having **fewer off-target effects**, thereby potentially reducing adverse events compared to conventional fibrates.

#### References:

1. Tomita Y, et al. *Biomedicines* 2020.



## SPPARMα Pemaifibrate

This slide illustrates **pemaifibrate's** potential to block three key pathological processes in diabetic retinopathy: **vascular permeability, neovascularization, and ischemia**. Pemaifibrate elevated **FGF21** levels, which helped **prevent pathological neovascularization**, reduce **retinal ischemia**, and **maintain retinal function**.

Another group similarly reported that pemaifibrate suppressed **vascular leakage, inflammation, and apoptosis** in a rat model.

These findings collectively suggest that pemaifibrate effectively targets multiple pathways involved in DR progression.

### References:

Tomita Y, et al. *Biomedicines* 2020.

1. Tomita, et al. *IJMS* 2019.


2. Tomita, et al. *IJMS* 2020.

3. Shiono, et al. *Sci Rep* 2020.

4. Lee, et al. *FASEB* 2022.

5. Lee, et al. *IJMS* 2021.





## Therapeutic targeting of cellular senescence in DME: phase 1 clinical trial

### (A) Patient Flow Diagram.

A total of 28 patients were screened. Of these, 8 patients with diabetic macular edema (DME) each received a single intravitreal injection of UBX1325. Best-corrected visual acuity (BCVA; C) and central subfield thickness (CST; D) were measured (mean  $\pm$  s.e.m.) over a 24-week follow-up period. CST data reflect measurements in the study eye only, as a standardized central reading was not performed for the fellow eye.

### (B) Representative SD-OCT Imaging.

Shown here are baseline (top) and 24-week (bottom) SD-OCT images from a patient who demonstrated a 108- $\mu\text{m}$  reduction in CST and an 11-letter improvement in BCVA (ETDRS) by the end of the study.


### (E) Schematic of the Senescence Hypothesis in DME.

During diabetes, senescent endothelial cells (ECs) accumulate in retinal vessels, perpetuating microinflammation and blood–retina barrier (BRB) breakdown, ultimately compromising visual function. UBX1325, a small-molecule BCL-xL inhibitor, selectively eliminates these senescent cells (senolysis), thereby promoting vascular remodeling and restoration of retinal integrity.

### References:

1. Crespo-Garcia, et al. *Nat Med* 2024.





## Topical treatment of DME using dexamethasone ophthalmic suspension: a randomized, double-masked, vehicle-controlled study

### Study Design:

- **Objective:** To evaluate the efficacy of OCS-01 (topical dexamethasone) in diabetic macular edema (DME).
- **Design:** Multicenter, double-masked, randomized Phase 2 trial.
- **Participants:** 144 patients with DME (OCS-01: n=99, Vehicle: n=45), treated for 12 weeks (1 drop, 3 times daily).

### Key Findings:

- **CMT Reduction:** OCS-01 significantly reduced central macular thickness ( $-53.6 \mu\text{m}$  vs.  $-16.8 \mu\text{m}$ ,  $p=0.0115$ , 12 weeks).
- **Visual Acuity Improvement:** OCS-01 showed a trend toward better BCVA (best corrected visual acuity) improvement ( $+2.6$  vs.  $+1.0$  ETDRS letters,  $p=0.125$ , 12 weeks)
- **Safety:** Well tolerated, with intraocular pressure elevation as the most common adverse event.

### Conclusion:

OCS-01 effectively reduces macular thickness and may improve vision, particularly in patients with lower baseline BCVA. A Phase 2/3 study is ongoing to confirm these findings in a larger patient population.

### References:

1. Stefansson E, et al. *Acta Ophthalmologica* 2022.



**Others**

**SECTION**

**7**

**R<sup>3</sup>i**

Residual Risk Reduction Initiative

## Recommended eye examinations for patients with diabetes mellitus

Diabetes Type	Recommended Initial Evaluation	Recommended Follow-up*
Type 1 <sup>†</sup>	5 years after diagnosis	Yearly
Type 2 <sup>‡</sup>	At time of diagnosis	Yearly
Pregnancy <sup>‡</sup> (type 1 or type 2)	Soon after conception and early in the first trimester	No retinopathy to mild or moderate NPDR: every 3-12 months Severe NPDR or worse: every 1-3 months

Abnormal findings may dictate frequent follow-up examinations.

† Pubertal patients require increased vigilance due to increased risk of progression.

‡ Women who develop gestational diabetes do not require an eye examination during pregnancy and do not appear to be at increased risk for DR during pregnancy.

Lim JI, et al. *Ophthalmology* 2025.

**R3i**  
Retinoid Risk Reduction Initiative

## Recommended eye examinations for patients with diabetes mellitus

In type 1 diabetes, retinopathy risk correlates with the duration of disease and tends to accelerate during puberty, though vision-threatening changes are uncommon before that stage. Annual examinations are generally advised starting 5 years after the initial diagnosis.

In type 2 diabetes, retinopathy may already be present at the time of diagnosis due to an often indeterminate onset, necessitating a comprehensive examination at diagnosis and at least yearly thereafter.


During pregnancy, preexisting diabetes can lead to retinopathy progression, so patients should be examined and counseled before conception or early in the first trimester, with follow-up intervals based on disease severity. Women with gestational diabetes alone typically do not require specific ophthalmic evaluation during pregnancy.

After each examination, clinicians should discuss findings with the patient, classify both eyes by retinopathy severity and macular edema, and determine the appropriate timing for interventions and future follow-up.

**Abbreviations:** NPDR = nonproliferative DR

**References:** 1. Lim JI, et al. *Ophthalmology* 2025.

## The referral rate of diabetes mellitus (DM) patients to ophthalmologists remains low in Japan



Sugiyama T, *Diabetes Res Clin Pract* 2019.  
Ihara-Sugiyama N, *J Diabetes Investig* 2023.

Only 40% of diabetes patients receiving treatment have undergone a fundus examination by an ophthalmologist.

In contrast, the percentage of fundus examinations conducted during ophthalmology visits is as high as 92.1%–98.7%.

➤ It is essential for physicians to refer diabetic patients to ophthalmologists to ensure proper eye care and prevent vision-threatening complications.

**R<sup>3</sup>i**  
Realist Risk Reduction Initiative

## The referral rate of diabetes mellitus (DM) patients to ophthalmologists remains low in Japan

Based on a large-scale database study, only about 40% of treated diabetes patients in Japan undergo a fundus examination by an ophthalmologist, whereas 92.1–98.7% of those who visit an ophthalmologist actually receive this exam. This gap suggests that many diabetic patients are not being referred for specialized eye care, potentially delaying early detection and treatment of diabetic retinopathy.

Consequently, timely referral from primary care or other specialties to ophthalmologists is crucial, as is reinforcing the need for regular eye examinations to prevent vision-threatening complications.

### References:

1. Sugiyama T, *Diabetes Res Clin Pract* 2019.
2. Ihara-Sugiyama N, *J Diabetes Investig* 2023.

# Collaboration between physicians and ophthalmologists is essential

## Recommendation for the Frequency of Ophthalmology Visits

Classification	Frequency of visit
No Diabetic Retinopathy (DR)	1 / 1 year
Mild-moderate NPDR	1 / 6 months
Severe NPDR	1 / 2 months
Proliferative Diabetic Retinopathy (PDR)	1 / 1 month



Diabetic Eye Record Book

The Committee of Guidelines for the Japanese Society of Ophthalmic Diabetology, Nippon Ganka Gakkai Zasshi, 2020.



# Collaboration between physicians and ophthalmologists is essential

The **Diabetic Eye Record Book** is an essential tool for managing diabetic retinopathy (DR) in patients with diabetes. It allows for better communication between healthcare providers, ensuring timely eye examinations and appropriate interventions.

## Conclusion

- While remarkable advances in diagnosis and treatment have dramatically improved the outlook for patients with diabetic retinopathy, vigilance remains essential. Consistent screening, optimized glycemic control, and appropriate intervention are critical in preventing vision loss.
- This booklet has provided a snapshot of our current understanding of DR but the field is constantly evolving. By staying informed about the latest developments in DR management and maintaining a proactive approach to patient care, we can significantly reduce the burden of this disease.

**R<sup>3</sup>i**

Residual Risk Reduction Initiative

## Conclusion

While *remarkable* advances in diagnosis and treatment have dramatically improved the outlook for patients with diabetic retinopathy, vigilance remains essential. Consistent screening, optimized glycemic control, and appropriate intervention are critical in preventing vision loss.

This booklet has provided a snapshot of our current understanding of DR but the field is constantly evolving. By staying informed about the latest developments in DR management and maintaining a proactive approach to patient care, we can significantly reduce the burden of this disease.





## Abbreviations

<b>ACE</b>	Angiotensin-converting enzyme
<b>ARB</b>	Angiotensin II receptor blocker
<b>BCVA</b>	Best corrected visual acuity
<b>BRB</b>	Blood-retina barrier
<b>CKD</b>	Chronic kidney disease
<b>CRT</b>	Central retinal thickness
<b>CST</b>	Central subfield thickness
<b>DME</b>	Diabetic macular edema
<b>DM</b>	Diabetes mellitus
<b>DR</b>	Diabetic retinopathy
<b>DRD</b>	Diabetic retinal disease
<b>DRN</b>	Diabetic retinal neurodegeneration
<b>eGFR</b>	Estimated glomerular filtration rate
<b>ERG</b>	Electroretinogram
<b>ETDRS</b>	Early Treatment Diabetic Retinopathy Study
<b>FA</b>	Fluorescein angiography
<b>FFA</b>	Fundus Fluorescein Angiography
<b>FGF</b>	Fibroblast growth factor
<b>GLP-1</b>	Glucagon-like peptide-1
<b>GIP</b>	Glucose-dependent insulintropic polypeptide
<b>HIF</b>	Hypoxia-inducible factor
<b>ICDR</b>	International Clinical Diabetic Retinopathy
<b>ILM</b>	Inner limiting membrane
<b>IOP</b>	Intraocular pressure

<b>IVTA</b>	Intravitreal triamcinolone acetonide
<b>MAFLD</b>	Metabolic dysfunction-associated fatty liver disease
<b>NPA</b>	Non-perfusion area
<b>NPDR</b>	Non-proliferative diabetic retinopathy
<b>NVG</b>	Neovascular glaucoma
<b>OCT</b>	Optical coherence tomography
<b>OCTA</b>	Optical coherence tomography angiography
<b>PDR</b>	Proliferative diabetic retinopathy
<b>PDGF</b>	Platelet-derived growth factor
<b>PKC</b>	Protein kinase C
<b>PPAR<math>\alpha</math></b>	Peroxisome proliferator-activated receptor alpha
<b>PRP</b>	Panretinal photocoagulation
<b>RAS</b>	Renin-angiotensin system
<b>SDM</b>	Subthreshold diode laser micropulse photocoagulation
<b>SGLT2i</b>	Sodium-glucose cotransporter 2 inhibitor
<b>SMC</b>	Smooth muscle cell
<b>SPPARM<math>\alpha</math></b>	Selective peroxisome proliferator-activated receptor alpha modulator
<b>SRD</b>	Serous retinal detachment
<b>STTA</b>	Sub-Tenon triamcinolone acetonide
<b>TRD</b>	Tractional retinal detachment
<b>TRP</b>	Targeted retinal photocoagulation
<b>VA</b>	Visual acuity
<b>VEGF</b>	Vascular endothelial growth factor
<b>VEGFR</b>	Vascular endothelial growth factor receptor
<b>VTDR</b>	Vision-threatening diabetic retinopathy



**R3i**

Residual Risk Reduction initiative